- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00526058
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol (FUTURA)
August 17, 2018 updated by: B. Braun Medical Inc.
Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use under the approved indication of the acute reduction of LDL-cholesterol from the plasma in populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements between the approved H.E.L.P. system and the modified H.E.L.P. system.
The secondary study endpoints are clinical lab profiles and device parameters analyzed at specific time points throughout the study.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
- Hartford Hospital
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
23 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is between 25 and 70 years of age (inclusive) at the time of randomization.
- Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria.
- Subject has received a minimum of two consecutive bi-monthly* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system >30 days prior to the screening visit.
- Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study.
- Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver.
Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence.
- Every 14 days (±2 days)
Exclusion Criteria:
- A History of a known sensitivity to heparin or ethylene oxide.
- A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count < 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers).
- Females who are pregnant or lactating.
- Subjects< 106 lbs. or <48.2 kg in body weight; or whose weight is >1.5 times their ideal weight.
- Certain cardiac impairments such as congestive heart failure, major arrhythmia, or diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24 hours apart.
- Renal insufficiency defined as creatinine greater >2.0 mg/dlL or is dependent upon renal dialysis.
- Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides >500 mg/dL.
- Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including Immune system suppression or compromise, that could preclude survival to study completion.
- History of stroke within 6 months of the screening visit.
- Received thrombolytic treatment < 7 days of screening.visit.
- Taken or requires a prohibited treatment < 30 days prior to the Screening Visit, or requires a prohibited treatment at anytime during the course of the study.
- Neutropenia (neutrophil count < 0.5 x109/L).
- History of liver disease or serum ALT and/or AST > 2X upper limit of normal range.
- History of dementia.
- History of anemia (value outside the lower normal range).
- acetyl salicylic acid (ASA) > 325 mg/day.
- Subject currently enrolled in another investigational study (does not apply to PMS for Secura device).
- Subject with any other medical condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.
- Subject is unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: A (Secura then Futura)
The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
|
Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
|
Other: B (Futura then Secura)
The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
|
Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.
Time Frame: Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..
|
Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..
|
|
Percent Change of the Pre and Post Treatment Value
Time Frame: Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.
|
The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements.
Blood samples for LDL-cholesterol determination will be obtained before and after each treatment.
The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance.
|
Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Lab Profiles (Pre- and Post-Treatment)
Time Frame: Analyzed at specific time points throughout the study from week 0 to week 24.
|
Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein.
|
Analyzed at specific time points throughout the study from week 0 to week 24.
|
Device Parameters
Time Frame: Analyzed at specific time points throughout the study from week 0 to week 24.
|
Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session.
|
Analyzed at specific time points throughout the study from week 0 to week 24.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patrick Moriarty, M.D., University of Kansas Medical Center
- Principal Investigator: Paul Thompson, M.D., Hartford Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs. 2002 Dec;25(12):1180-8. doi: 10.1177/039139880202501210.
- Susca M. Heparin-Induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: technique and first clinical results. Ther Apher. 2001 Oct;5(5):387-93. doi: 10.1046/j.1526-0968.2001.00371.x.
- Schettler V, Monazahian M, Wieland E, Thomssen R, Muller GA. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher. 2001 Oct;5(5):384-6. doi: 10.1046/j.1526-0968.2001.00374.x.
- Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 2001 Oct;158(2):495-8. doi: 10.1016/s0021-9150(01)00633-5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2007
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
September 5, 2007
First Submitted That Met QC Criteria
September 5, 2007
First Posted (Estimate)
September 6, 2007
Study Record Updates
Last Update Posted (Actual)
September 14, 2018
Last Update Submitted That Met QC Criteria
August 17, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Clotrimazole
- Miconazole
Other Study ID Numbers
- LDLc-A-US2-0406
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineCompletedPrimary HypercholesterolemiaUnited States
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Merck Sharp & Dohme LLCTerminated
-
Danone JapanCompletedHealthy | Mild HypercholesterolemiaJapan
Clinical Trials on Secura then Futura
-
Eisai Co., Ltd.Completed
-
Zoll Medical CorporationCompletedHeart FailureUnited States
-
Lung InstituteWithdrawnCOPD | Chronic Bronchitis | Emphysema or COPDUnited States
-
Radford UniversityRecruitingKinematics | Musculoskeletal Equilibrium | Posture | ElectromyographyUnited States
-
University of California, San DiegoCompletedCognitive ControlUnited States
-
University of LouisvilleCompletedGeneral Anesthesia With Endotracheal Intubation in SurgeryUnited States
-
University of California, San DiegoCompletedPhantom Limb Pain | Residual Limb PainUnited States
-
University of WashingtonRecruiting
-
Otto Bock France SNCEuraxi PharmaCompletedTransradial AmputationFrance
-
Hospices Civils de LyonCompleted